{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:51:08Z","timestamp":1792482668243,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd015092","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000}}],"reference-count":283,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015092.pub2","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:16:19Z","timestamp":1761783379000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Semaglutide for adults living with obesity"],"prefix":"10.1002","volume":"2025","author":[{"given":"Javier","family":"Bracchiglione","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"},{"name":"Iberoamerican Cochrane Centre; Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Instituto de Salud Carlos III; Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Meza","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan VA","family":"Franco","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK - D\u00fcsseldorf Subunit, Institute of General Practice, Centre for Health and Society, Medical Faculty; Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Micaela","family":"Escobar Liquitay","sequence":"additional","affiliation":[{"name":"Research Department; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Novik A","sequence":"additional","affiliation":[{"name":"School of Medicine; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"},{"name":"School of Medicine; Universidad Andr\u00e9s Bello; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Ocara Vargas","sequence":"additional","affiliation":[{"name":"School of Medicine; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lazcano","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Poloni","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Rinaldi Langlotz","sequence":"additional","affiliation":[{"name":"School of Medicine; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Roqu\u00e9-Figuls","sequence":"additional","affiliation":[{"name":"Iberoamerican Cochrane Centre; Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"},{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Instituto de Salud Carlos III; Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio R","family":"Munoz","sequence":"additional","affiliation":[{"name":"Department of Public Health-CIGES; Faculty of Medicine, Universidad de La Frontera; Temuco Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-5549","authenticated-orcid":false,"given":"Eva","family":"Madrid","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Iberoam\u00e9rica, Interdisciplinary Centre for Health Studies (CIESAL); Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"},{"name":"Iberoamerican Cochrane Centre; Institut de Recerca Sant Pau (IR SANT PAU); Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S2213-8587(24)00150-5","article-title":"Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial","volume":"12","author":"Eckard","year":"2024","journal-title":"Lancet. Diabetes & Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2024","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD015092.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD015092.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD015092.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"155931","DOI":"10.1016\/j.metabol.2024.155931","article-title":"DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"159","author":"Handelsman","year":"2024","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"2019","key":"10.1002\/14651858.CD015092.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","article-title":"Pharmacotherapy of obesity: available medications and drugs under investigation","volume":"92","author":"Pilitsi","year":"2019","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0009|cit9","unstructured":"World Health Organization Obesity and overweight www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0010|cit10","unstructured":"World Health Organization Obesity www.who.int\/news-room\/facts-in-pictures\/detail\/6-facts-on-obesity"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"19778","DOI":"10.1038\/s41598-020-75213-3","article-title":"The ongoing nutrition transition thwarts long-term targets for food security, public health and environmental protection","volume":"10","author":"Bodirsky","year":"2020","journal-title":"Scientific Reports"},{"issue":"10173","key":"10.1002\/14651858.CD015092.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s0140-6736(18)32822-8","article-title":"The global syndemic of obesity, undernutrition, and climate change: the Lancet commission report","volume":"393","author":"Swinburn","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD015092.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/ijerph14040435","article-title":"Economic burden of obesity: a systematic literature review","volume":"14","author":"Tremmel","year":"2017","journal-title":"International Journal of Environmental Research and Public Health"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhealeco.2011.10.003","article-title":"The medical care costs of obesity: an instrumental variables approach","volume":"31","author":"Cawley","year":"2012","journal-title":"Journal of Health Economics"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"w822","DOI":"10.1377\/hlthaff.28.5.w822","article-title":"Annual medical spending attributable to obesity: payer-and service-specific estimates","volume":"28","author":"Finkelstein","year":"2009","journal-title":"Health Affairs (Project Hope)"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectrum"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/MED.0000000000000192","article-title":"Obesity medications: what does the future look like?","volume":"22","author":"Butsch","year":"2015","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"issue":"4","key":"10.1002\/14651858.CD015092.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD015092.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiological Reviews"},{"issue":"10","key":"10.1002\/14651858.CD015092.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: unraveling the diverse neural circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.2741\/2785","article-title":"Dipeptidyl peptidase IV (DPP IV\/CD26) is a cell-surface plasminogen receptor","volume":"13","author":"Gonzalez-Gronow","year":"2008","journal-title":"Frontiers in Bioscience"},{"issue":"20","key":"10.1002\/14651858.CD015092.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4239\/wjd.v7.i20.572","article-title":"Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity","volume":"7","author":"Anandhakrishnan","year":"2016","journal-title":"World Journal of Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD015092.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0024|cit24","first-page":"S2","article-title":"Defining success in obesity management","volume":"21 Suppl 1","author":"R\u00f6ssner","year":"1997","journal-title":"International Journal of Obesity and Related Metabolic Disorders"},{"issue":"20","key":"10.1002\/14651858.CD015092.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMp2400978","article-title":"Fair allocation of GLP-1 and dual GLP-1-GIP receptor agonists","volume":"390","author":"Emanuel","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0026|cit26","unstructured":"US Food & Drug Administration - Assistance with FDA regulation www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209637Orig1s000TOC.cfm"},{"issue":"7","key":"10.1002\/14651858.CD015092.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes. The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"82\u20133","DOI":"10.1056\/NEJMe1506236","article-title":"Another agent for obesity - will this time be different?","volume":"373","author":"Siraj","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0029|cit29","unstructured":"Wegovy | European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wegovy#authorisation-details"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0030|cit30","unstructured":"Wegovy highlights of prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s011lbl.pdf"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis","volume":"47","author":"Tan","year":"2023","journal-title":"International Journal of Obesity"},{"issue":"6","key":"10.1002\/14651858.CD015092.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s13300-020-00816-y","article-title":"Drug therapy in obesity: a review of current and emerging treatments","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Therapy"},{"issue":"25 Pt B","key":"10.1002\/14651858.CD015092.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"103024","DOI":"10.1016\/j.dsx.2024.103024","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes: a systematic review of real-world evidence","volume":"18","author":"Singh","year":"2024","journal-title":"Diabetes & Metabolic Syndrome"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-019-00812-7","article-title":"Benefit-risk assessment of obesity drugs: focus on glucagon-like peptide-1 receptor agonists","volume":"42","author":"Christensen","year":"2019","journal-title":"Drug Safety"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/dom.14990","article-title":"Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes","volume":"25","author":"Aroda","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/14656566.2019.1695779","article-title":"An evaluation of liraglutide including its efficacy and safety for the treatment of obesity","volume":"21","author":"Lin","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3-4","key":"10.1002\/14651858.CD015092.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"202\u201330","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Review of Diabetic Studies"},{"issue":"9","key":"10.1002\/14651858.CD015092.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs - FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"217\u201332","DOI":"10.1586\/17446651.2015.1057502","article-title":"A systematic review of the safety of incretin-based therapies in type 2 diabetes","volume":"11","author":"Evans","year":"2016","journal-title":"Expert Review of Endocrinology & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD015092.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"906\u20138","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Current Obesity Reports"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012204.pub2","article-title":"Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus","author":"Hemmingsen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015092.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011798.pub2","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease","author":"Lo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD015092.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006423.pub2","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/CLEP.S391819","article-title":"Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review","volume":"14","author":"Xie","year":"2022","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0048|cit48","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0049|cit49","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"issue":"71","key":"10.1002\/14651858.CD015092.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD015092.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015092","article-title":"Glucagon-like peptide-1 analogues for overweight or obese adults","author":"Madrid","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0052|cit52","unstructured":"Madrid E Franco J Meza N Bracchiglione J Ocara M Escobar-Liquitay C Glucagon-like peptide-1 (GLP-1) analogues for adult people with obesity: protocol for asystematic review with meta-analysis Available from https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420250654193"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"e12961","DOI":"10.1111\/obr.12961","article-title":"Core outcome set for behavioural weight management interventions for adults with overweight and obesity: standardised reporting of lifestyle weight management interventions to aid evaluation (STAR-LITE)","volume":"21","author":"Mackenzie","year":"2019","journal-title":"Obesity Reviews"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0054|cit54","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Technical Supplement to Chapter 4: Searching for and selecting studies (last updated September 2024). In: Higgins JPT Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-04"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12020-021-02945-1","article-title":"Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis","volume":"75","author":"Zhong","year":"2022","journal-title":"Endocrine"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/dom.15386","article-title":"Efficacy and safety of semaglutide 2.4\u2009mg for weight loss in overweight or obese adults without diabetes: an updated systematic review and meta-analysis including the 2-year STEP 5 trial","volume":"26","author":"Qin","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD015092.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1055\/a-2303-8558","article-title":"Efficacy and safety of once-weekly subcutaneous semaglutide in overweight or obese adults: a systematic review with meta-analysis","volume":"132","author":"Dorneles","year":"2024","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"issue":"222","key":"10.1002\/14651858.CD015092.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"1","author":"Moiz","year":"2024","journal-title":"American Journal of Cardiology,"},{"issue":"4","key":"10.1002\/14651858.CD015092.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40256-024-00647-3","article-title":"Cardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: a meta-analysis of randomized controlled trials","volume":"24","author":"Oliveira Almeida","year":"2024","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"4","key":"10.1002\/14651858.CD015092.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s11096-022-01428-1","article-title":"Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis","volume":"44","author":"Arastu","year":"2022","journal-title":"International Journal of Clinical Pharmacy"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0061|cit61","unstructured":"Covidence Veritas Health Innovation 2025"},{"issue":"mar07 3","key":"10.1002\/14651858.CD015092.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"j2998","DOI":"10.1136\/bmj.j2998","article-title":"Enhancing the usability of systematic reviews by improving the consideration and description of interventions","volume":"358","author":"Hoffmann","year":"2017","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/bmjebm-2019-111230","article-title":"What to do with a clinical trial with conflicts of interest","volume":"25","author":"Lundh","year":"2020","journal-title":"BMJ Evidence-Based Medicine."},{"key":"10.1002\/14651858.CD015092.pub2-BIB0065|cit65","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook"},{"issue":"oct18 2","key":"10.1002\/14651858.CD015092.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0067|cit67","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-06#section-6-1"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0068|cit68","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0070|cit70","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-10"},{"issue":"7644","key":"10.1002\/14651858.CD015092.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0072|cit72","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-12"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7382","key":"10.1002\/14651858.CD015092.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0075|cit75","first-page":"10.7326\/ANNALS","article-title":"GRADE certainty ratings: thresholds rather than categories of contextualization (GRADE guidance 41)","volume":"Jul 1","author":"Hultcrantz","year":"2025","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0076|cit76","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-14"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0077|cit77","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jclinepi.2015.12.006","article-title":"Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments","volume":"74","author":"Santesso","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"McComsey GA Sattar A Albar Z Gilani KA Labbato D Foster T 1984. Effects of semaglutide on adipose tissue in HIV-associated lipohypertrophy Open Forum Infectious Diseases 2023 S67 S68 10.1093\/ofid\/ofad500.111","DOI":"10.1093\/ofid\/ofad500.111"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0081|cit81","unstructured":"Effects of semaglutide in HIV-associated lipohypertrophy https:\/\/clinicaltrials.gov\/study\/NCT04019197 2019"},{"issue":"10148","key":"10.1002\/14651858.CD015092.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.1007\/s00125-018-4693-0","article-title":"HbA1c changes in subjects with obesity without diabetes receiving semaglutide for weight management","volume":"61 Suppl 1","author":"Mosenzon","year":"2018","journal-title":"Diabetologia"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015092.pub2-BIB0084|cit84","article-title":"A randomized, phase II, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes","volume":"392","author":"O'Neil","year":"2018","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1007\/s00125-018-4693-0","article-title":"A randomised, phase 2, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes","volume":"61 Suppl 1","author":"Wilding","year":"2018","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"S589","DOI":"10.1007\/s00125-018-4693-0","article-title":"The effect of semaglutide on liver enzymes in subjects with obesity and elevated alanine aminotransferase: data from a randomised phase 2 trial","volume":"61 Suppl 1","author":"Monk-Hansen","year":"2018","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"445A","DOI":"10.1002\/hep.30257","article-title":"High-sensitivity C-reactive protein reductions in subjects with elevated alanine aminotransferase receiving semaglutide for treatment of obesity in a phase 2 trial","volume":"68 Suppl 1","author":"Newsome","year":"2018","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0088|cit88","unstructured":"A randomised, double-blind, parallel group, placebo-controlled trial comparing semaglutide 2.4 mg with semaglutide placebo both administered s.c. once-weekly in subjects with established CVdisease and overweight or obesity https:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=Mjc1MzU=&Enc=&userName=CTRI\/2018\/10\/016193 2018"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0089|cit89","unstructured":"Wilding J Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S A randomised, phase 2, placebo-and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes Obesity Facts 2018 48 10.1159\/000489691"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0090|cit90","unstructured":"Wilding J Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S High number of responders with pharmacotherapy-induced weight loss of at least 15% in a placebo-controlled, dose- ranging study of semaglutide in subjects with obesity Obesity Facts 2018 280-1 10.1159\/000489691"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000489691","article-title":"Changes in SF-36 scores among subjects receiving semaglutide for treatment of obesity","volume":"12","author":"McGowan","year":"2019","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0092|cit92","unstructured":"Birkenfeld AL Wharton S McGowan B Giwercman CC Heerdegen JC Endahl L Weight loss and nausea in subjects receiving semaglutide for the treatment of obesity 26th European Congress on Obesity 2019 247 7"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000489691","article-title":"HbA1c changes in subjects with obesity without diabetes receiving semaglutide (SEMA) for weight management","volume":"12 Suppl 1","author":"Mosenzon","year":"2019","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0094|cit94","unstructured":"Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus https:\/\/clinicaltrials.gov\/study\/NCT02453711 2015"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0096|cit96","unstructured":"Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-001540-38\/DE 2014"},{"issue":"10403","key":"10.1002\/14651858.CD015092.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0098|cit98","unstructured":"Research study to investigate how well semaglutide tablets taken once daily work in people who are overweight or living with obesity (OASIS 1) https:\/\/clinicaltrials.gov\/study\/NCT05035095 2024"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0099|cit99","unstructured":"Research study to investigate how well semaglutide tablets taken once daily work in people who are overweight or living with obesity (OASIS) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-002953-11 2020"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0100|cit100","unstructured":"Research study to investigate how well semaglutide tablets taken once daily work in people who are overweight or living with obesity (OASIS 1) https:\/\/clinicaltrials.gov\/study\/NCT05035095 2021"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"1","author":"Lingvay","year":"2022","journal-title":"Obesity"},{"issue":"17","key":"10.1002\/14651858.CD015092.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","article-title":"The effect of semaglutide on mortality and COVID-19-related deaths: an analysis from the SELECT trial","volume":"84","author":"Scirica","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD015092.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.jacc.2024.08.022","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT): outcomes by sex","volume":"84","author":"Verma","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0104|cit104","unstructured":"Semaglutide effects on heart disease and stroke in patients with overweight or obesity https:\/\/clinicaltrials.gov\/study\/NCT03574597 2018"},{"issue":"10454","key":"10.1002\/14651858.CD015092.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2337\/dc24-0491","article-title":"Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial","volume":"47","author":"Kahn","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jcjd.2024.09.026","article-title":"Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial","volume":"48 Suppl 7","author":"Lau","year":"2024","journal-title":"Canadian Journal of Diabetes"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"S457EP","DOI":"10.1097\/HEP.0000000000001076","article-title":"Semaglutide improves liver enzymes and fatty liver index in patients with obesity and cardiovascular disease - results from the select trial","volume":"80 Suppl 1","author":"Meyhofer","year":"2024","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/j.jcjd.2024.09.023","article-title":"The effect of semaglutide on mortality and COVID-19-related deaths - a pre-specified analysis from the SELECT trial","volume":"48 Suppl 7","author":"Morin","year":"2024","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0111|cit111","unstructured":"Semaglutide effects on heart disease and stroke in patients with overweight or obesity https:\/\/clinicaltrials.gov\/study\/NCT03574597 2018"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.118518","article-title":"Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the select trial","volume":"395 Suppl 1","author":"Plutzky","year":"2024","journal-title":"Atherosclerosis"},{"issue":"0370465","key":"10.1002\/14651858.CD015092.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000538577","article-title":"Long-term weight loss in the SELECT trial: semaglutide 2.4 mg vs placebo over 208 weeks in a global population of 17,604 participants","volume":"17 Suppl 1","author":"Ryan","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000538577","article-title":"Serious adverse events and safety profile of semaglutide vs placebo in the SELECT study","volume":"17 Suppl 1","author":"Kushner","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jcjd.2024.09.118","article-title":"Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis - a subgroup analysis from the SELECT trial","volume":"48 Suppl 7","author":"Tsoukas","year":"2024","journal-title":"Canadian Journal of Diabetes"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"i1128","DOI":"10.1093\/ndt\/gfae069.692","article-title":"Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial","volume":"39 Suppl 1","author":"Colhoun","year":"2024","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD015092.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.orcp.2024.09.083","article-title":"Semaglutide and cardiovascular outcomes in patients with overweight or obesity who do not have diabetes","volume":"18","author":"Leung","year":"2024","journal-title":"Obesity Research & Clinical Practice"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD015092.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.orcp.2024.09.021","article-title":"Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis - a subgroup analysis from the SELECT trial","volume":"18","author":"Leung","year":"2024","journal-title":"Obesity Research & Clinical Practice"},{"issue":"7","key":"10.1002\/14651858.CD015092.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015092.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000538577","article-title":"Relevance of body weight and weight change on cardiovascular benefit with semaglutide: a pre-specified analysis of the SELECT trial","volume":"17 Suppl 1","author":"Deanfield","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0123|cit123","unstructured":"SELECT - Semaglutide effects on heart disease and stroke in patients with overweight or obesity https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-003380-35 2017"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0124|cit124","unstructured":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-003380-35 2017"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0125|cit125","unstructured":"Trial to study the effect of semaglutide on reducing urinary albumin excretion in people with serious overweight without diabetes https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2021-001247-27 2021"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0126|cit126","unstructured":"Semaglutide and albuminuria reduction trial in obese individuals without diabetes (SMART) https:\/\/clinicaltrials.gov\/study\/NCT04889183 2021"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0127|cit127","unstructured":"Semaglutide and albuminuria reduction trial in obese individuals without diabetes https:\/\/onderzoekmetmensen.nl\/en\/node\/50899\/pdf 2021"},{"issue":"11","key":"10.1002\/14651858.CD015092.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/oby.23329","article-title":"Greater weight loss associated with greater physical functioning improvement in the STEP 1 trial","volume":"29 Suppl 2","author":"Sharma","year":"2021","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000515911","article-title":"Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)","volume":"14 Suppl 1","author":"Kushner","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1007\/s11695-022-06096-8","article-title":"Once-weekly semaglutide 2.4mg improved metabolic syndrome in adults with overweight or obesity: post hoc analysis of the STEP 1 trial","volume":"32 Suppl 1","author":"Khan","year":"2022","journal-title":"Obesity Surgery"},{"issue":"18 Suppl 1","key":"10.1002\/14651858.CD015092.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/S0735-1097(21)02982-X","article-title":"Treatment with semaglutide 2.4 mg leads to improvements in cardiometabolic risk factors in the step 1 trial","volume":"77","author":"Kosiborod","year":"2021","journal-title":"JACC"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.2337\/db21-81-OR","article-title":"Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight\/obesity in the STEP 1 trial","volume":"70 Suppl 1","author":"Perreault","year":"2021","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05519-y","article-title":"Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trial","volume":"64 Suppl 1","author":"Perreault","year":"2021","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0135|cit135","unstructured":"STEP 1: research study investigating how well semaglutide works in people suffering from overweight or obesity https:\/\/clinicaltrials.gov\/study\/NCT03548935 2018"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"e12477","DOI":"10.1111\/cob.12477","article-title":"Confirmatory psychometric evaluations of the impact of weight on quality of life-lite clinical trials version (IWQOL-lite-CT)","volume":"11","author":"Kolotkin","year":"2021","journal-title":"Clinical Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/oby.23329","article-title":"Greater weight loss associated with greater physical functioning improvement in the STEP 1 trial","volume":"29 Suppl 2","author":"Sharma","year":"2021","journal-title":"Obesity"},{"issue":"11","key":"10.1002\/14651858.CD015092.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"126-7","DOI":"10.1159\/000515911","article-title":"Improvement of the 10-year atherosclerotic cardiovascular disease risk with once-weekly semaglutide 2.4 mg in adults with overweight or obesity - post-hoc analysis of the STEP 1 trial","volume":"14 Suppl 1","author":"Davies","year":"2021","journal-title":"Obesity Facts"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"125-6","DOI":"10.1159\/000515911","article-title":"Treatment with semaglutide 2.4 mg leads to improvements in cardiometabolic risk factors in the STEP 1 trial","volume":"14 Suppl 1","author":"Garvey","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"138-9","DOI":"10.1159\/000515911","article-title":"Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in adults with overweight or obesity (STEP 1)","volume":"14 Suppl 1","author":"Wilding","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1210\/jendso\/bvab048.046","article-title":"Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)","volume":"3 Suppl 1","author":"Kushner","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000515911","article-title":"Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial","volume":"14 Suppl 1","author":"Le Roux","year":"2021","journal-title":"Obesity Facts"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD015092.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/dom.15426","article-title":"Treatment effect of semaglutide 2.4 mg on health-related quality of life from STEP 1 SF-6D derived from SF-36 with Australian weights","volume":"26","author":"Kral","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD015092.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP Trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/oby.23946","article-title":"Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: a post hoc subgroup analysis","volume":"32","author":"Kushner","year":"2024","journal-title":"Obesity"},{"issue":"4","key":"10.1002\/14651858.CD015092.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/oby.23732","article-title":"Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: post hoc analyses of the STEP 1 randomized trial","volume":"31","author":"McGowan","year":"2023","journal-title":"Obesity"},{"issue":"7","key":"10.1002\/14651858.CD015092.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/oby.24042","article-title":"Efficacy and safety of semaglutide 2.4 mg by race and ethnicity: a post hoc analysis of three randomized controlled trials","volume":"32","author":"Rubino","year":"2024","journal-title":"Obesity"},{"issue":"7","key":"10.1002\/14651858.CD015092.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/dom.15620","article-title":"Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: patient-reported outcomes from the STEP 1-4 trials","volume":"26","author":"Rubino","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13502","article-title":"Gender differences in weight loss using anti-obesity medications","volume":"23","author":"Susanto","year":"2022","journal-title":"Obesity Reviews"},{"issue":"18 Suppl 1","key":"10.1002\/14651858.CD015092.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0735-1097(21)02963-6","article-title":"Improvement of the 10-year atherosclerotic cardiovascular disease risk with once-weekly semaglutide 2.4 mg in adults with overweight or obesity - post-hoc analysis of the STEP 1 trial","volume":"77","author":"Verma","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"101733727","key":"10.1002\/14651858.CD015092.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"101737","DOI":"10.1016\/j.eclinm.2022.101737","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials","volume":"55","author":"Verma","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2337\/db22-2-LB","article-title":"Semaglutide 2.4 mg reduces the 10-year T2D risk in people with overweight\/obesity s","volume":"71","author":"Garvey","year":"2022","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"A10","DOI":"10.1210\/jendso\/bvab048.018","article-title":"Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in adults with overweight or obesity (STEP 1)","volume":"5","author":"Wilding","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"48-9","DOI":"10.1159\/000515911","article-title":"Semaglutide 2.4 mg induces weight loss and improves body composition across age groups in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial","volume":"14 Suppl 1","author":"Dicker","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"52-54","DOI":"10.1159\/000515911","article-title":"Semaglutide 2.4 mg once weekly improves patient-reported outcome measures of physical functioning in adults with overweight or obesity in the STEP 1 trial","volume":"14 Suppl 1","author":"Wharton","year":"2021","journal-title":"Obesity Facts"},{"issue":"2 Suppl 2","key":"10.1002\/14651858.CD015092.pub2-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.nupar.2023.03.160","article-title":"Association entre une meilleure perte de poids et une meilleure am\u00e9lioration de la fonction physique","volume":"37","author":"Ritz","year":"2023","journal-title":"Nutrition Clinique et Metabolisme"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0168-8278(23)00435-X","article-title":"Prevalence of, and effect of semaglutide on, features of nonalcoholic steatohepatitis in patients with obesity with and without type 2 diabetes: analysis of data from two randomised placebo-controlled trials using SomaSignal tests","volume":"78","author":"Schattenberg","year":"2023","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/oby.23328","article-title":"Weight loss outcomes with semaglutide 2.4 mg in moderate or severe obesity in step 1 and 2","volume":"29 Suppl 2","author":"Le Roux","year":"2021","journal-title":"Obesity"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1016\/j.jval.2021.11.1175","article-title":"POSC350 health utility values in the STEP 1-4 trials of semaglutide 2.4 mg in obesity","volume":"25","author":"Meincke","year":"2022","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.4103\/2230-8210.342310","article-title":"Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)","volume":"26 Suppl 1","author":"Suresh","year":"2022","journal-title":"Indian Journal of Endocrinology and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD015092.pub2-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1016\/j.jcjd.2023.10.380","article-title":"Treatment with semaglutide 2.4 mg leads to improvements in cardiometabolic risk factors in the step 1 trial","volume":"47","author":"Zarruk","year":"2023","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"I248","DOI":"10.1093\/eurjpc\/zwae175.172","article-title":"Blood pressure effect of semaglutide in patients with hypertension: an individual patient data analysis of randomised controlled trials","volume":"31","author":"Kennedy","year":"2024","journal-title":"European Journal of Preventive Cardiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/oby.23626","article-title":"Efficacy and safety of semaglutide 2.4 mg by race and ethnicity","volume":"30 Suppl 1","author":"Rubino","year":"2022","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1007\/s11695-021-05591-8","article-title":"Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)","volume":"31 Suppl 1","author":"Garvey","year":"2021","journal-title":"Obesity Surgery"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1007\/s11695-021-05591-8","article-title":"Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)","volume":"31 Suppl 1","author":"Garvey","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0171|cit171","unstructured":"STEP-1: research study investigating how well semaglutide works in people suffering from overweight or obesity CTRI\/2018\/07\/014765 2018"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0172|cit172","unstructured":"Research study investigating how well semaglutide works in people suffering from overweight or obesity EUCTR2017-003436-36-PL 2018"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0173|cit173","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-023-01306-4","article-title":"Semaglutide 2.4 mg induces weight loss and improves body composition across age groups in adults with overweight or obesity: post-hoc analysis of the STEP 1 trial","volume":"47","author":"Stuart","year":"2023","journal-title":"International Journal of Obesity (2005)"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0174|cit174","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2023.06.377","article-title":"Treatment with semaglutide 2.4 mg leads to improvements in cardiometabolic risk factors in the STEP 1 trial","volume":"39","author":"Zarruk","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"118-19","DOI":"10.1159\/000515911","article-title":"Beneficial effect of semaglutide 2.4 mg once weekly on patient-reported outcome measures of weight-related and health-related quality of life in adults with overweight or obesity in the STEP 1 trial","volume":"14 Suppl 1","author":"Rubino","year":"2021","journal-title":"Obesity Facts"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/dom.15090","article-title":"The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials","volume":"25","author":"Bjorner","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1007\/s00125-022-05755-w","article-title":"Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity","volume":"65","author":"Garvey","year":"2022","journal-title":"Diabetologia"},{"issue":"10","key":"10.1002\/14651858.CD015092.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.2337\/dc21-1785","article-title":"Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program","volume":"45","author":"Perreault","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s11695-023-06662-8","article-title":"Efficacy and safety of semaglutide 2.4 mg by race and ethnicity","volume":"33","author":"Salih","year":"2023","journal-title":"Obesity Surgery"},{"issue":"9","key":"10.1002\/14651858.CD015092.pub2-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet. Diabetes & Endocrinology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0181|cit181","unstructured":"Research study looking at how well semaglutide works in people living with obesity and prediabetes https:\/\/clinicaltrials.gov\/study\/NCT05040971 2021"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000538577","article-title":"STEP 10 trial: semaglutide 2.4 mg provided a superior reduction vs placebo in body weight and reversion to normoglycaemia in participants with obesity and prediabetes","volume":"17","author":"McGowan","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0183|cit183","unstructured":"Research study looking at how well semaglutide works in people living with obesity and prediabetes https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2020-002939-29 2020"},{"issue":"10278","key":"10.1002\/14651858.CD015092.pub2-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000515911","article-title":"Efficacy and safety of semaglutide 2.4 mg once-weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)","volume":"14 Suppl 1","author":"Davies","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1007\/s00125-022-05755-w","article-title":"Associations between weight loss and glycaemic control with once weekly semaglutide 1.0 mg and 2.4 mg in the STEP 2 trial","volume":"65 Suppl 1","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"A10","DOI":"10.1210\/jendso\/bvab048.019","article-title":"Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)","volume":"5","author":"Davies","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1007\/s00125-021-05519-y","article-title":"Treatment with once-weekly semaglutide 2.4 mg improves cardiometabolic risk factors in adults with overweight or obesity and type 2 diabetes: STEP 2 post-hoc analysis","volume":"64","author":"Deanfield","year":"2021","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"S234","DOI":"10.1007\/s00125-021-05519-y","article-title":"Effect of semaglutide 2.4 mg on achievement of weight loss and HbA1c <7%, without hypoglycaemia, in adults with overweight\/obesity and type 2 diabetes in STEP 2","volume":"64","author":"Goldenberg","year":"2021","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0190|cit190","doi-asserted-by":"publisher","DOI":"10.2337\/db21-80-OR","article-title":"Treatment with once-weekly semaglutide 2.4 mg improves cardiometabolic risk factors in adults with overweight\/obesity and type 2 diabetes: step 2 post-hoc analysis","volume":"70 Suppl 1","author":"Kushner","year":"2021","journal-title":"Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1016\/j.ekir.2022.01.357","article-title":"Pos-336 semaglutide 2.4 mg and 1.0 mg improved albuminuria in adults with overweight\/obesity and type 2 diabetes in STEP 2","volume":"7","author":"Lambers Heerspink","year":"2022","journal-title":"Kidney International Reports"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1007\/s00125-021-05519-y","article-title":"Influence of baseline characteristics on weight loss with semaglutide 2.4 mg in adults with overweight\/obesity and type 2 diabetes (STEP 2)","volume":"64","author":"Le Roux","year":"2021","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0193|cit193","doi-asserted-by":"publisher","DOI":"10.2337\/db21-83-OR","article-title":"Influence of baseline characteristics on weight loss with semaglutide 2.4 mg in adults with overweight\/obesity and type 2 diabetes (STEP 2)","volume":"70 Suppl 1","author":"Lingvay","year":"2021","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1007\/s00125-021-05519-y","article-title":"Effect of semaglutide 2.4 mg on glucose metabolism and body weight in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial","volume":"64","author":"Pedersen","year":"2021","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0195|cit195","doi-asserted-by":"publisher","DOI":"10.2337\/db21-82-OR","article-title":"Effect of semaglutide 2.4 mg on glucose metabolism and body weight in adults with overweight\/obesity and type 2 diabetes in the STEP 2 trial","volume":"70 Suppl 1","author":"Perreault","year":"2021","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0196|cit196","doi-asserted-by":"publisher","DOI":"10.2337\/db21-84-OR","article-title":"Semaglutide 2.4 mg improves health-related quality of life in adults with overweight\/obesity and type 2 diabetes in the STEP 2 trial","volume":"70 Suppl 1","author":"Rubino","year":"2021","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"S248","DOI":"10.1007\/s00125-021-05519-y","article-title":"Semaglutide 2.4 mg improves health-related quality of life in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial","volume":"64","author":"Rubino","year":"2021","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0198|cit198","doi-asserted-by":"publisher","DOI":"10.2337\/db21-85-OR","article-title":"Semaglutide 2.4 mg improves patient reported outcome measures of physical functioning in adults with overweight\/obesity and type 2 diabetes in the STEP 2 trial","volume":"70 Suppl 1","author":"Wharton","year":"2021","journal-title":"Diabetes"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0199|cit199","doi-asserted-by":"crossref","unstructured":"Wharton S Meincke HH Kushner RF Oral TK Pedersen SD Rubino DM Semaglutide 2.4 mg improves patient-reported outcome measures of physical functioning in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial Diabetologia 2021 S248 S248 10.1007\/s00125-021-05519-y","DOI":"10.2337\/db21-85-OR"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0200|cit200","first-page":"S9","article-title":"Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)","volume":"26 Suppl 1","author":"Rahman","year":"2022","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0201|cit201","unstructured":"STEP 2 : research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity https:\/\/clinicaltrials.gov\/study\/NCT03552757 2018"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0202|cit202","unstructured":"Research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-003414-10\/GB 2018"},{"issue":"14","key":"10.1002\/14651858.CD015092.pub2-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"49-50","DOI":"10.1159\/000515911","article-title":"Semaglutide 2.4 mg and intensive behavioural therapy in subjects with overweight or obesity (STEP 3)","volume":"14 Suppl 1","author":"Frias","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/oby.23057","article-title":"Semaglutide 2.4 mg and intensive behavioral therapy in subjects with overweight or obesity (STEP 3)","volume":"28 Suppl 2","author":"Wadden","year":"2020","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0206|cit206","unstructured":"Research study to look at how well semaglutide is at lowering weight when taken together with an intensive lifestyle program https:\/\/clinicaltrials.gov\/study\/NCT03611582 2018"},{"issue":"14","key":"10.1002\/14651858.CD015092.pub2-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0208|cit208","unstructured":"Research study investigating how well semaglutide works in people suffering from overweight or obesity https:\/\/ClinicalTrials.gov\/show\/NCT03548987 2018"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000515911","article-title":"Weight-loss maintenance with once-weekly semaglutide 2.4 mg in adults with overweight or obesity reaching maintenance dose (STEP 4)","volume":"14 Suppl 1","author":"Rubino","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000515911","article-title":"Continued treatment with semaglutide 2.4 mg leads to sustained improvements in cardiometabolic risk factors in the STEP 4 trial","volume":"14 Suppl 1","author":"Garvey","year":"2021","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"9-10","DOI":"10.1002\/oby.23328","article-title":"Continued semaglutide 2.4 mg once weekly improved health related quality of life in the STEP 4 trial","volume":"29 Suppl 2","author":"Sharma","year":"2021","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1210\/jendso\/bvab048.013","article-title":"Clinically-relevant weight loss is achieved independently of early weight loss response to once- weekly subcutaneous semaglutide 2.4 mg (STEP 4)","volume":"5","author":"Mosenzon","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"A63","DOI":"10.1210\/jendso\/bvab048.129","article-title":"Weight loss maintenance with once-weekly semaglutide 2.4 mg in adults with overweight or obesity reaching maintenance dose (STEP 4)","volume":"5","author":"Rubino","year":"2021","journal-title":"Journal of the Endocrine Society"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"133-4","DOI":"10.1159\/000515911","article-title":"Clinically-relevant weight loss is achieved independently of early weight loss response to once-weekly subcutaneous semaglutide 2.4 mg (STEP 4)","volume":"14 Suppl 1","author":"Kushner","year":"2021","journal-title":"Obesity Facts"},{"issue":"18","key":"10.1002\/14651858.CD015092.pub2-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0735-1097(21)02965-X","article-title":"Continued treatment with semaglutide 2.4 mg leads to sustained improvements in cardiometabolic risk factors in the step 4 trial","volume":"77","author":"Verma","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0217|cit217","unstructured":"Research study investigating how well semaglutide works in people suffering from overweight or obesity https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-003436-36 2018"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0218|cit218","unstructured":"Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NL-OMON46356 2018"},{"issue":"10","key":"10.1002\/14651858.CD015092.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0220|cit220","unstructured":"A randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, multicenter, dose-ranging study to evaluate the safety and efficacy of JNJ-64565111 in non-diabetic severely obese subjects https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-003616-39 2018"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/oby.23328","article-title":"Two-year effect of semaglutide 2.4 mg vs placebo in adults with overweight or obesity: STEP 5","volume":"29 Suppl 2","author":"Garvey","year":"2021","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0222|cit222","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06662-8","article-title":"Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial","volume":"33 Suppl 1","author":"Dimitriadis","year":"2023","journal-title":"Obesity Surgery"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0223|cit223","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-023-01306-4","article-title":"Two-year effect of semaglutide 2.4 mg vs placebo in adults with overweight or obesity: STEP-5","volume":"47","author":"Papamargaritis","year":"2023","journal-title":"International Journal of Obesity"},{"issue":"10","key":"10.1002\/14651858.CD015092.pub2-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/j.cjca.2023.06.393","article-title":"Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomized controlled STEP 5 trial","volume":"39","author":"Azar","year":"2023","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41366-023-01306-4","article-title":"Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight\/obesity: STEP-5","volume":"47","author":"Abbott","year":"2023","journal-title":"Obesity"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/oby.23673","article-title":"Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight\/obesity: STEP 5","volume":"31","author":"Wharton","year":"2023","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0227|cit227","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1007\/s00125-022-05755-w","article-title":"Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial","volume":"65","author":"Batterham","year":"2022","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0228|cit228","unstructured":"Two-year research study investigating how well semaglutide works in people suffering from overweight or obesity https:\/\/clinicaltrials.gov\/study\/NCT03693430 2018"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0229|cit229","doi-asserted-by":"publisher","first-page":"42-3","DOI":"10.1002\/oby.23328","article-title":"Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight\/obesity: STEP 5","volume":"29 Suppl 2","author":"Wharton","year":"2021","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0230|cit230","unstructured":"STEP 5: Two-year research study investigating how well semaglutide works in people suffering from overweight or obesity https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-003726-32 2018"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0231|cit231","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet. Diabetes & Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD015092.pub2-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"e12589","DOI":"10.1111\/cob.12589","article-title":"Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial","volume":"13","author":"Kolotkin","year":"2023","journal-title":"Clinical Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0233|cit233","unstructured":"STEP 6: research study investigating how well semaglutide works in people living with overweight or obesity https:\/\/ClinicalTrials.gov\/show\/NCT03811574 2019"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0234|cit234","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet. Diabetes & Endocrinology"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0235|cit235","doi-asserted-by":"publisher","DOI":"10.1159\/000530456","article-title":"Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly Asian population with overweight or obesity in the STEP 7 randomised clinical trial","volume":"16","author":"Mu","year":"2023","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0236|cit236","unstructured":"Research study of how well semaglutide works in people living with overweight or obesity https:\/\/clinicaltrials.gov\/study\/NCT04251156 2020"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0237|cit237","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/oby.23328","article-title":"Semaglutide 2.4 mg vs liraglutide 3.0 mg for weight management in overweight or obesity (STEP 8)","volume":"29 Suppl 2","author":"Rubino","year":"2021","journal-title":"Obesity"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0238|cit238","unstructured":"Research study to investigate how well semaglutide works compared to liraglutide in people living with overweight or obesity https:\/\/clinicaltrials.gov\/study\/NCT04074161 2019"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0239|cit239","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06662-8","article-title":"Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8)","volume":"33 Suppl 1","author":"Idris","year":"2023","journal-title":"Obesity Surgery"},{"issue":"11","key":"10.1002\/14651858.CD015092.pub2-BIB0240|cit240","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/dom.14809","article-title":"Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial","volume":"24","author":"Snitker","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0241|cit241","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1007\/s00125-022-05755-w","article-title":"Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8)","volume":"65","author":"Rubino","year":"2022","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0242|cit242","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2337\/db22-1413-P","article-title":"Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycemia in adults with overweight\/obesity vs. liraglutide 3.0 mg (STEP 8)","volume":"71 Suppl 1","author":"Rosenstock","year":"2022","journal-title":"Diabetes"},{"issue":"17","key":"10.1002\/14651858.CD015092.pub2-BIB0243|cit243","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0244|cit244","unstructured":"Research study looking at how well semaglutide works in people suffering from obesity and knee osteoarthritis https:\/\/clinicaltrials.gov\/study\/NCT05064735 2021"},{"issue":"6","key":"10.1002\/14651858.CD015092.pub2-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.joca.2024.03.003","article-title":"Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: results: from the STEP 9 randomised clinical trial","volume":"32","author":"Bliddal","year":"2024","journal-title":"Osteoarthritis and Cartilage"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0246|cit246","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000538577","article-title":"Semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: results from the STEP 9 randomised clinical trial","volume":"17 Suppl 1","author":"Bliddal","year":"2024","journal-title":"Obesity Facts"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0247|cit247","unstructured":"Research study looking at how well semaglutide works in people suffering from obesity and knee osteoarthritis https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-000204-11\/FR 2020"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0249|cit249","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD015092.pub2-BIB0250|cit250","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program","volume":"84","author":"Schou","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD015092.pub2-BIB0251|cit251","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD015092.pub2-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials","volume":"84","author":"Verma","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD015092.pub2-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","article-title":"Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD015092.pub2-BIB0254|cit254","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related hfpef: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD015092.pub2-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction","volume":"82","author":"Butler","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0256|cit256","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cardfail.2023.10.465","article-title":"Effects of semaglutide across the range of left ventricular ejection fraction in obesity phenotype of heart failure with preserved ejection fraction: the STEP-HFpEF trial","volume":"30","author":"Butler","year":"2024","journal-title":"Journal of Cardiac Failure"},{"issue":"9","key":"10.1002\/14651858.CD015092.pub2-BIB0257|cit257","doi-asserted-by":"publisher","first-page":"2358\u201365","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0258|cit258","unstructured":"Research study to investigate how well semaglutide works in people living with obesity and heart failure https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number%3A2019-004452-11 2020"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0259|cit259","unstructured":"Research study to investigate how well semaglutide works in people living with heart failure and obesity https:\/\/ClinicalTrials.gov\/show\/NCT04788511 2021"},{"issue":"8 Pt 1","key":"10.1002\/14651858.CD015092.pub2-BIB0260|cit260","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype","volume":"11","author":"Kosiborod","year":"2023","journal-title":"JACC: Heart Failure"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0261|cit261","unstructured":"Effect of semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NL-OMON51952 2020"},{"issue":"35","key":"10.1002\/14651858.CD015092.pub2-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"European Heart Journal"},{"issue":"10437","key":"10.1002\/14651858.CD015092.pub2-BIB0263|cit263","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0264|cit264","unstructured":"Research study to look at how well semaglutide works in people living with heart failure, obesity and type 2 diabetes https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004170-22\/HU 2021"},{"issue":"5","key":"10.1002\/14651858.CD015092.pub2-BIB0265|cit265","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.orcp.2024.09.085","article-title":"Once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes: main results from the STEP-HFpEF DM trial","volume":"18","author":"Sindone","year":"2024","journal-title":"Obesity Research & Clinical Practice"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0266|cit266","unstructured":"Effect of semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes https:\/\/onderzoekmetmensen.nl\/en\/trial\/51963 2021"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0267|cit267","unstructured":"nl\/trial\/51963 Effect of semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes https:\/\/onderzoekmetmensen.nl\/nl\/trial\/51963 2021"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0268|cit268","unstructured":"Aronne LJ Horn DB Le Roux CW Ho W Falcon BL Gomez Valderas E SURMOUNT-5 Trial Investigators Tirzepatide as compared with semaglutide for the treatment of obesity New England Journal of Medicine 1 11 10.1056\/NEJMoa2416394 40353578"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0269|cit269","unstructured":"A study of tirzepatide (LY3298176) in participants with obesity or overweight with weight related comorbidities (SURMOUNT-5) https:\/\/clinicaltrials.gov\/study\/NCT05822830 2022"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0270|cit270","unstructured":"National Academies of S Medicine; Health and Medicine Division; Food and Nutrition Board; Roundtable on Obesity S The science, strengths, and limitations of body mass index Callahan EA Translating Knowledge of Foundational Drivers of Obesity into Practice: Proceedings of a Workshop Series Washington (DC) National Academies Press (US) 37639520"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0271|cit271","doi-asserted-by":"publisher","first-page":"e084654","DOI":"10.1136\/bmj-2025-084654","article-title":"Beyond body mass index: rethinking doctors\u2019 advice for weight loss","volume":"389","author":"Franco","year":"2025","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD015092.pub2-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0273|cit273","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015092.pub2-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/jrsm.1611","article-title":"Commercial funding and estimated intervention effects in randomized clinical trials: systematic review of meta-epidemiological studies","volume":"14","author":"Hansen Nejstgaard","year":"2023","journal-title":"Research Synthesis Methods"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0275|cit275","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD015092.pub2-BIB0276|cit276","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13098-023-01195-7","article-title":"Efficacy and tolerability of the subcutaneous semaglutide for type 2 diabetes patients: an updated systematic review and meta-analysis","volume":"15","author":"Hu","year":"2023","journal-title":"Diabetology & Metabolic Syndrome"},{"issue":"21","key":"10.1002\/14651858.CD015092.pub2-BIB0277|cit277","doi-asserted-by":"publisher","first-page":"e38236","DOI":"10.1097\/MD.0000000000038236","article-title":"Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: a meta-analysis","volume":"103","author":"Huang","year":"2024","journal-title":"Medicine"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0278|cit278","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: a systematic literature review","volume":"25","author":"Feier","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0279|cit279","doi-asserted-by":"publisher","first-page":"108529","DOI":"10.1016\/j.jdiacomp.2023.108529","article-title":"Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: a systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials","volume":"37","author":"Patoulias","year":"2023","journal-title":"Journal of Diabetes and Its Complications"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0280|cit280","doi-asserted-by":"publisher","first-page":"110605","DOI":"10.1016\/j.diabres.2023.110605","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"8","key":"10.1002\/14651858.CD015092.pub2-BIB0281|cit281","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/imj.16126","article-title":"Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review","volume":"53","author":"Stretton","year":"2023","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0282|cit282","unstructured":"National Institute for Health and Care Excellence (NICE) Semaglutide for managing overweight and obesity: technology appraisal guidance https:\/\/www.nice.org.uk\/guidance\/ta875\/resources\/semaglutide-for-managing-overweight-and-obesity-pdf-82613674831813 2023"},{"key":"10.1002\/14651858.CD015092.pub2-BIB0283|cit283","unstructured":"Wegovy\u00ae (semaglutide) injection 2.4 mg List Price & Insurance Coverage explained | NovoCare\u00ae https:\/\/www.novocare.com\/obesity\/products\/wegovy\/let-us-help\/explaining-list-price.html [accessed 15 July 2024]"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:18:15Z","timestamp":1786436295000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015092.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":283,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015092.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}